Effects of Apelin and VEGF on Retinal Vein Occlusion in Monkeys
Author Information
Author(s): Zhao Tong, Lu Qiang, Tao Yong, Liang Xiao-Ying, Wang Kai, Jiang Yan-Rong
Primary Institution: People’s Hospital, Peking University
Hypothesis
To examine the intraocular distribution of bevacizumab and investigate the effects of IVB on apelin and VEGF in CRVO of monkey eyes.
Conclusion
Bevacizumab can be detected in the iris and choroid after four weeks of injection, and it may partially suppress apelin, which plays a role in retinal neovascularization during CRVO development.
Supporting Evidence
- Bevacizumab was detected in the iris and choroid vessels four weeks after injection.
- Apelin expression was significantly higher in the CRVO group compared to normal eyes.
- Intravitreal injection of bevacizumab down-regulated apelin mRNA expression.
Takeaway
This study looked at how a medicine called bevacizumab affects certain proteins in monkey eyes with a condition that blocks blood flow in the retina. It found that the medicine can help reduce these proteins over time.
Methodology
The study involved creating a CRVO model in six Rhesus monkeys and injecting bevacizumab into three of them, followed by various analyses including immunohistochemistry and PCR.
Potential Biases
Potential immunological interference due to the use of a humanized antibody in monkeys.
Limitations
The study is preliminary with a small sample size and lacks certain tests like western blotting; results may not fully translate to humans.
Participant Demographics
Six Rhesus monkeys were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website